Gene Signature Can Predict Breast Cancer Responsiveness to New Class of Drugs, Scientists Say

Scientists have discovered a gene signature in certain types of breast cancer that can be used to determine the likelihood of these tumors responding to treatment with a new class of anti-cancer medications known as Smac-mimetics. Triple-negative breast cancer (TNBC) was one of the best responders, suggesting these agents may be adopted as a new line of therapy for this difficult-to-treat form of breast cancer in the future, investigators noted. Their findings were reported in…

You must be logged in to read/download the full post.